Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs

The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.”